1-3 of 3
Vanessa Bolejack, MPH
Close
Sort by
Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD
Journal: Blood
Blood (2007) 110 (11): 3449.
https://doi.org/10.1182/blood.V110.11.3449.3449
Published: 2007
Journal Articles

S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group.

Mohamad A. Hussein, MD, Andrzej J. Jakubowiak, MD, PhD, Vanessa Bolejack, MPH, Jeff Zonder, MD, John Crowley, PhD, Bart Barlogie
Journal: Blood
Blood (2006) 108 (11): 3088.
https://doi.org/10.1182/blood.V108.11.3088.3088
Published: 2006
Journal Articles

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Michael J. Burns, BS, BA, Vanessa Bolejack, MPH, Klaus A. Hollmig, MD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Francesca Elice, MD, Guido J. Tricot, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2552.
https://doi.org/10.1182/blood.V106.11.2552.2552
Published: 2005